Abstract
Introduction: Jumping translocations are rare cytogenetic events in hematologic malignancies, involving nonreciprocal translocation of a donor chromosome onto two or more recipient chromosomes. Case Presentation: In this paper, we report the first-ever case of a jumping translocation involving the long arm of chromosome 3 in a patient with mantle cell lymphoma. The basic clone had the translocation t(11;14)(q13;q32) and a der(13)t(3;13)(q12;p11), and the three subclones had an additional jumping translocation, involving the translocation of 3q12 onto recipient chromosomes 14p, 15p, and der(14)t(11;14), thus resulting in partial trisomy and tetrasomy 3q. Conclusion: Although the underlying mechanism for the formation of jumping translocations is not well understood, their presence is usually associated with poor prognosis and clonal evolution and additional data are needed for their better clinical management.
Journal Section:
Novel Insights from Clinical Practice
References
1.
Lejeune
J
, Maunoury
C
, Prieur
M
, Van den Akker
J
. Translocation sautese (5p;15q), (8q;15q), (12q;15q)
. Ann Genet
. 1979
;22
(4
):210
–3
.2.
Gray
BA
, Bent-Williams
A
, Wadsworth
J
, Maiese
RL
, Bhatia
A
, Zori
RT
. Fluorescence in situ hybridization assessment of the telomeric regions of jumping translocations in a case of aggressive B-cell non-Hodgkin lymphoma
. Cancer Genet Cytogenet
. 1997
;98
(1
):20
–7
. 3.
Rosenwald
A
, Ott
G
, Katzenberger
T
, Siebert
R
, Kalla
J
, Kuse
R
, et al. Jumping translocation of 1q as the sole aberration in a case of follicular lymphoma
. Cancer Genet Cytogenet
. 1999
;108
(1
):53
–6
. 4.
Fan
YS
, Rizkalla
K
, William
BF
, Engel
CJ
. Jumping translocations of 11q in acute myeloid leukemia and 1q in follicular lymphoma
. Cancer Genet Cytogenet
. 2000
;118
(1
):35
–41
. 5.
Manola
KN
, Georgakakos
VN
, Stavropoulou
C
, Spyridonidis
A
, Angelopoulou
MK
, Vlachadami
I
, et al. Jumping translocations in hematological malignancies: a cytogenetic study of five cases
. Cancer Genet Cytogenet
. 2008
;187
(2
):85
–94
. 6.
Sanford
D
, DiNardo
CD
, Tang
G
, Cortes
JE
, Verstovsek
S
, Jabbour
E
, et al. Jumping translocations in myeloid malignancies associated with treatment resistance and poor survival
. Clin Lymphoma Myeloma Leuk
. 2015
;15
(9
):556
–62
. 7.
Sánchez Prieto
I
, López Rubio
M
, Arranz
E
, Ayala
R
, Callejas Charavía
M
, Martín Guerrero
Y
, et al. Jumping translocation in a patient with acute leukemia and fatal evolution
. Case Rep Oncol
. 2020
;13
(2
):1026
–30
. 8.
Berger
R
, Bernard
OA
. Jumping translocations
. Genes Chromosomes Cancer
. 2007
;46
(8
):717
–23
. 9.
Yeung
CCS
, Deeg
HJ
, Pritchard
C
, Wu
D
, Fang
M
. Jumping translocations in myelodysplastic syndromes
. Cancer Genet
. 2016
;209
(9
):395
–402
. 10.
Aledo
R
, Aurias
A
, Chrétien
B
, Dutrillaux
B
. Jumping translocation of chromosome 14 in a skin squamous cell carcinoma from a xeroderma pigmentosum patient
. Cancer Genet Cytogenet
. 1988
;33
(1
):29
–33
. 11.
Petković
I
, Konja
J
, Dominis
M
, Kaštelan
M
. Jumping translocations involving 11q in a non-Hodgkin lymphoma
. Cancer Genet Cytogenet
. 1999
;114
(2
):121
–5
. 12.
Whang-Peng
J
, Lee
EC
, Sieverts
H
, Magrath
IT
. Burkitt’s lymphoma in AIDS: cytogenetic study
. Blood
. 1984
;63
(4
):818
–22
. 13.
Roland
B
, Pinto
A
, Bowen
T
. Jumping translocation involving 1q in a small noncleaved cell lymphoma
. Am J Hum Genet
. 1992
;51
:A69
.14.
Shikano
T
, Arioka
H
, Kobayashi
R
, Naito
H
, Ishikawa
Y
. Jumping translocations of 1q in Burkitt lymphoma and acute nonlymphocytic leukemia
. Cancer Genet Cytogenet
. 1993
;71
(1
):22
–6
. 15.
Wlodarska
I
, Mecucci
C
, De Wolf-Peeters
C
, Verhoef
G
, Weier
HU
, Cassiman
JJ
, et al. Jumping” translocation of 9q in a case of follicular lymphoma
. Cancer Genet Cytogenet
. 1994
;76
(2
):140
–4
. 16.
Sawyer
JR
, Swanson
CM
, Koller
MA
, North
PE
, William Ross
S
. Centromeric instability of chromosome 1 resulting in multibranched chromosomes, telomeric fusions, and “jumping” translocations of 1q in a human immunodeficiency virus-related non-Hodgkin’s lymphoma
. Cancer
. 1995
;76
(7
):1238
–44
. 17.
Kakazu
N
, Kito
K
, Hitomi
T
, Oita
J
, Nishida
K
, Masuda
K
, et al. Characterization of complex chromosomal abnormalities in B-cell lymphoma by a combined spectral karyotyping (SKY) analysis and fluorescence in situ hybridization (FISH) using a 14q telomere probe
. Am J Hematol
. 2000
;65
(4
):291
–7
. 18.
Bessenyei
B
, Ujfalusi
A
, Balogh
E
, Olah
E
, Szegedi
I
, Kiss
C
. Jumping translocation of chromosome 1q associated with good clinical outcome in a case of Burkitt leukemia
. Cancer Genet
. 2011
;204
(4
):207
–10
. 19.
Swerdlow
S
, Campo
E
, Harris
NL
, Jaffe
ES
, Pileri
SA
, Stein
A
, et al, editors. Mantle cell lymphoma
. WHO classification of tumours of haematopoietic and lymphoid tissues
. Lyon
: IARC
; 2008
. Vol. Vol. 4
. p. 229
–32
.20.
Zelenetz
AD
, Gordon
LI
, Wierda
WG
, Abramson
JS
, Advani
RH
, Andreadis
CB
, et al. Non-Hodgkin’s lymphomas, version 4.2014
. J Natl Compr Canc Netw
. 2014
;12
(9
):1282
–303
. 21.
Zlamalikova
L
, Moulis
M
, Salek
D
, Jarkovsky
J
, Smarda
J
, Smardova
J
. Expression of D-type cyclins in mantle cell and diffuse large B-cell lymphomas
. Oncol Rep
. 2016
;35
(5
):2673
–80
. 22.
Hastings
RJ
, Moore
S
, Chia
N
, editors. ISCN 2024: an international System for human cytogenomic nomenclature
. Basel
: Karger
; 2020
.23.
Onciu
M
, Schlette
E
, Medeiros
LJ
, Abruzzo
LV
, Keating
M
, Lai
R
. Cytogenetic findings in mantle cell lymphoma cases with a high level of peripheral blood involvement have a distinct pattern of abnormalities
. Am J Clin Pathol
. 2001
;116
(6
):886
–92
. 24.
Salaverria
I
, Zettl
A
, Beà
S
, Moreno
V
, Valls
J
, Hartmann
E
, et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature
. J Clin Oncol
. 2007
;25
(10
):1216
–22
. 25.
Espinet
B
, Salaverria
I
, Beà
S
, Ruiz-Xivillé
N
, Balagué
O
, Salido
M
, et al. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma
. Genes Chromosomes Cancer
. 2010
;49
(5
):439
–51
. 26.
Li
S
, Xu
J
, You
MJ
. The pathologic diagnosis of mantle cell lymphoma
. Histol Histopathol
. 2021
;36
(10
):1037
–51
. 27.
Reis
MD
, Dubé
ID
, Pinkerton
PH
, Chen-Lai
J
, Robinson
JB
, Klock
RJ
, et al. Jumping” translocations involving band 3q13.3 in a case of acute monocytic leukemia
. Cancer Genet Cytogenet
. 1991
;51
(2
):189
–94
. 28.
Andreasson
P
, Höglund
M
, Jonson
T
, Békàssy
A
, Mitelman
F
, Johansson
B
. Molecular characterization of jumping translocations reveals spatial and temporal breakpoint heterogeneity
. Leukemia
. 1998
;12
(9
):1411
–6
. 29.
Schoch
C
, Trenn
G
, Haase
D
, Korsten
S
, Haferlach
T
, Reis
HE
, et al. De novo or therapy related AML? Different points of view discussed on a case of AML M2 with t(8;21) (q22;q22) and a jumping translocation involving chromosome band 3q21
. Ann Hematol
. 1996
;73
(Suppl 1
):A101
.30.
Batanian
JR
, Dunphy
CH
, Wall
DA
. Jumping translocations of 3q in acute promyelocytic leukemia
. Cancer Genet Cytogenet
. 1999
;108
(2
):149
–53
. 31.
Bernard
M
, Lemée
F
, Picard
F
, Ghandour
C
, Drenou
B
, Le Prise
PY
, et al. Jumping translocation in acute leukemia of myelomonocytic lineage: a case report and review of the literature
. Leukemia
. 2000
;14
(1
):119
–22
. 32.
McGrattan
P
, Humphreys
M
, Hull
D
. Unbalanced jumping translocation involving 3q in myeloproliferative disease
. Med Oncol
. 2009
;26
(2
):251
–5
. 33.
McGrattan
P
, Logan
A
, Humphreys
M
, Bowers
M
. Jumping translocation in acute monocytic leukemia (M5b) with alternative breakpoint sites in the long arm of donor chromosome 3
. Med Oncol
. 2010
;27
(3
):667
–72
. 34.
Zou
YS
, Ouahchi
K
, Lu
Y
, Liu
W
, Christensen
T
, Schappert
J
, et al. Jumping translocations of 3q21 in an acute monocytic leukemia (M5) patient reveal mechanisms of multistage telomere shortening in pathogenesis of AML
. Leuk Res
. 2012
;36
(1
):e31
–3
. 35.
Kjeldsen
E
. Characterization of an acquired jumping translocation involving 3q13.31-qter in a patient with de novo acute monocytic leukemia
. Exp Mol Pathol
. 2017
;103
(1
):14
–25
. 36.
Yoon
J
, Cho
EH
, Yun
JW
, Kim
HY
, Jang
JH
, Kim
HJ
, et al. LSAMP rearrangement in acute myeloid leukemia with a jumping translocation involving 3q13.31
. Ann Lab Med
. 2021
;41
(3
):342
–5
. 37.
Belnekar
M
, Virulkar
S
, Tulpule
S
, Kar
B
. Jumping translocation of 3q21 in a patient with acute myeloid leukemia and poor clinical outcome
. J Cancer Res Ther
. 2024
;20
(5
):1643
–6
. 38.
Chase
A
, Ernst
T
, Fiebig
A
, Collins
A
, Grand
F
, Erben
P
, et al. TFG, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals
. Haematologica
. 2010
;95
(1
):20
–6
. 39.
Chong
ML
, Cheng
H
, Xu
P
, You
H
, Wang
M
, Wang
L
, et al. TFG-RARA: a novel fusion gene in acute promyelocytic leukemia that is responsive to all-trans retinoic acid
. Leuk Res
. 2018
;74
:51
–4
. 40.
Zhang
L
, Yang
X
, Ge
X
, Li
B
, Zhang
H
, Li
J
, et al. CMSS1::FLT1 rearrangement leads to ligand-independent activation of FLT1 signaling in acute myeloid leukemia
. Am J Hematol
. 2023
;98
(12
):E380
–2
. 41.
Monni
O
, Oinonen
R
, Elonen
E
, Franssila
K
, Teerenhovi
L
, Joensuu
H
, et al. Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma
. Genes Chromosomes Cancer
. 1998
;21
(4
):298
–307
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
